Vaiman, E.E.,
Shnayder, N.A.,
Zhuravlev, N.M.,
Petrova, M.M.,
Asadullin, A.R.,
Al-Zamil, M.,
Garganeeva, N.R.,
Shipulin, G.A.,
Cumming, G.,
Nasyrova, R.F. (2022) of which is influenced by modifying factors (APs’ dose, duration of APs
therapy,
APs polytherapy
for developing targeted
therapy for neurological consequences of COVID-19 using miRNAs, since epigenetic changes
Ivanova, E.,
Gilyazova, I.,
Pavlov, V.,
Izmailov, A.,
Gimalova, G.,
Karunas, A.,
Prokopenko, I.,
Khusnutdinova, E. (2022) RNA processing. Biological-pathway-based PGSs will advance the development of innovative screening
systems